Preventive Health Care
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Patient Care Through Telepharmacy September 2016
Patient Care through Telepharmacy September 2016 Gregory Janes Objectives 1. Describe why telepharmacy started and how it has evolved with technology 2. Explain how telepharmacy is being used to provide better patient care, especially in rural areas 3. Understand the current regulatory environment around the US and what states are doing with regulation Agenda ● Origins of Telepharmacy ● Why now? ● Telepharmacy process ● Regulatory environment ● Future Applications Telepharmacy Prescription verification CounselingPrescription & verification Education History Origins of Telepharmacy 1942 Australia’s Royal Flying Doctor Service 2001 U.S. has first state pass telepharmacy regulation 2003 Canada begins first telepharmacy service 2010 Hong Kong sees first videoconferencing consulting services US Telepharmacy Timeline 2001 North Dakota first state to allow 2001 Community Health Association in Spokane, WA launches program 2002 NDSU study begins 2003 Alaska Native Medical Center program 2006 U.S. Navy begins telepharmacy 2012 New generation begins in Iowa Question #1 What was the first US state to allow Telepharmacy? a) Alaska b) North Dakota c) South Dakota d) Hawaii Question #1 What was the first US state to allow Telepharmacy? a) Alaska b) North Dakota c) South Dakota d) Hawaii NDSU Telepharmacy Study Study from 2002-2008 ● 81 pharmacies ○ 53 retail and 28 hospital ● Rate of dispensing errors <1% ○ Compared to national average of ~2% ● Positive outcomes, mechanisms could be improved Source: The North Dakota Experience: Achieving High-Performance -
A Tool to Help Clinicians Do What They Value Most
Health Information Technology: a Tool to Help Clinicians Do What They Value Most Health care professionals like you play a vital role in improving the health outcomes, quality of care, and the health care experience of patients. Health information technology (health IT) is an important tool that you can use to improve clinical practice and the health of your patients. Health IT can help health care professionals to do what you do best: provide excellent care to your patients. Research shows that when patients are Health IT encompasses a wide range of electronic tools that can help you: engaged in their health care, it can lead to • Access up-to-date evidence-based clinical guidelines and decision measurable improvements in safety and support quality. • Improve the quality of care and safety of your patients Source: Agency for Healthcare Research and Quality (AHRQ) • Provide proactive health maintenance for your patients • Better coordinate patients’ care with other providers through the secure and private sharing of clinical information. Health IT can help you to solve clinical problems with real-time data Quality improvement and clinical decision support rely on information about your patient population being readily available in digital form. Health IT can help you monitor your patients’ health status and make specific and targeted recommendations to improve your patients’ health. Access to real-time data through electronic health records and health IT will help you: A MAJORITY OF PROVIDERS • Use clinical decision support to highlight care options tailored to believe that electronic health information your patients has the potential to improve the quality of patient care and care coordination. -
PREVENTIVE CARE SERVICES Policy Number: PREVENTIVE 006.50 T0 Effective Date: June 1, 2018
UnitedHealthcare® Oxford Clinical Policy PREVENTIVE CARE SERVICES Policy Number: PREVENTIVE 006.50 T0 Effective Date: June 1, 2018 Table of Contents Page Related Policies INSTRUCTIONS FOR USE .......................................... 1 Breast Imaging for Screening and Diagnosing CONDITIONS OF COVERAGE ...................................... 1 Cancer BENEFIT CONSIDERATIONS ...................................... 2 Cardiovascular Disease Risk Tests COVERAGE RATIONALE ............................................. 2 Cytological Examination of Breast Fluids for Cancer DEFINITIONS .......................................................... 6 Screening APPLICABLE CODES ................................................. 8 Genetic Testing for Hereditary Cancer REFERENCES .......................................................... 50 POLICY HISTORY/REVISION INFORMATION ................ 51 Par Gastroenterologists Using Non-Par Anesthesiologists: In-Office & Ambulatory Surgery Centers Preventive Medicine and Screening Vaccines INSTRUCTIONS FOR USE This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. When deciding coverage, the member specific -
Colorectal Cancer Screening Algorithm
Colorectal Cancer Screening Page 1 of 6 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. This algorithm is not intended for individuals with a personal history of colorectal cancer 1. Note: Screening for adults age 76 to 85 years old should be evaluated on an individual basis by their health care provider to assess the risks and benefits of screen ing. Colorectal cancer screening is not recommended over age 85 years. TABLE OF CONTENTS Average Risk …………..………………...……………………..………………………………...Page 2 Increased Risk ………………………...…………………...………….………………………….Page 3 High Risk ………………………………………………………………………………………....Page 4 Suggested Readings …………………………………...……...………………………………….Page 5 Development Credits ………………………………………………….........................................Page 6 1 See the Colon or Rectal Cancer Treatment or Survivorship algorithms for the management of individuals with a personal history of colorectal cancer Department of Clinical Effectiveness V9 Approved by the Executive Committee of the Medical Staff on 09/21/2021 Colorectal Cancer Screening – Average Risk Page 2 of 6 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. -
Primary Screening for Breast Cancer with Conventional Mammography: Clinical Summary
Primary Screening for Breast Cancer With Conventional Mammography: Clinical Summary Population Women aged 40 to 49 y Women aged 50 to 74 y Women aged ≥75 y The decision to start screening should be No recommendation. Recommendation Screen every 2 years. an individual one. Grade: I statement Grade: B Grade: C (insufficient evidence) These recommendations apply to asymptomatic women aged ≥40 y who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation Risk Assessment (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Increasing age is the most important risk factor for most women. Conventional digital mammography has essentially replaced film mammography as the primary method for breast cancer screening Screening Tests in the United States. Conventional digital screening mammography has about the same diagnostic accuracy as film overall, although digital screening seems to have comparatively higher sensitivity but the same or lower specificity in women age <50 y. For women who are at average risk for breast cancer, most of the benefit of mammography results from biennial screening during Starting and ages 50 to 74 y. While screening mammography in women aged 40 to 49 y may reduce the risk for breast cancer death, the Stopping Ages number of deaths averted is smaller than that in older women and the number of false-positive results and unnecessary biopsies is larger. The balance of benefits and harms is likely to improve as women move from their early to late 40s. -
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry1
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) July 2018 Procedural Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353 Email: [email protected] https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Office of Communication, Outreach and Development Center for Biologics Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 71, Room 3128 Silver Spring, MD 20993-0002 Phone: 800-835-4709 or 240-402-8010 Email: [email protected] https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Office of Communication and Education CDRH-Division of Industry and Consumer Education Center for Devices and Radiological Health Food and Drug Administration 10903 New Hampshire Ave., Bldg. 66, Room 4621 Silver Spring, MD 20993-0002 Phone: 800-638-2041 or 301-796-7100; Fax: 301-847-8149 Email: [email protected] https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) July 2018 Procedural Contains Nonbinding Recommendations TABLE OF CONTENTS I. -
Health Information Technology
Published for 2020-21 school year. Health Information Technology Primary Career Cluster: Business Management and Technology Course Contact: [email protected] Course Code: C12H34 Introduction to Business & Marketing (C12H26) or Health Science Prerequisite(s): Education (C14H14) Credit: 1 Grade Level: 11-12 Focused Elective This course satisfies one of three credits required for an elective Graduation Requirements: focus when taken in conjunction with other Health Science courses. This course satisfies one out of two required courses to meet the POS Concentrator: Perkins V concentrator definition, when taken in sequence in an approved program of study. Programs of Study and This is the second course in the Health Sciences Administration Sequence: program of study. Aligned Student HOSA: http://www.tennesseehosa.org Organization(s): Teachers are encouraged to use embedded WBL activities such as informational interviewing, job shadowing, and career mentoring. Coordinating Work-Based For information, visit Learning: https://www.tn.gov/content/tn/education/career-and-technical- education/work-based-learning.html Available Student Industry None Certifications: 030, 031, 032, 034, 037, 039, 041, 052, 054, 055, 056, 057, 152, 153, Teacher Endorsement(s): 158, 201, 202, 203, 204, 311, 430, 432, 433, 434, 435, 436, 471, 472, 474, 475, 476, 577, 720, 721, 722, 952, 953, 958 Required Teacher None Certifications/Training: https://www.tn.gov/content/dam/tn/education/ccte/cte/cte_resource Teacher Resources: _health_science.pdf Course Description Health Information Technology is a third-level applied course in the Health Informatics program of study intended to prepare students with an understanding of the changing world of health care information. -
Understanding the Randomized Controlled Trials By
Breast Cancer Screening: Understanding the Randomized Controlled Trials By: Phoebe Freer, MD, Linda Moy, MD, FSBI, Wendy DeMartini, MD, FSBI, and the Screening Leadership Group Screening mammography has been shown to decrease breast cancer mortality across multiple trials, and across many different study designs. Despite this, some opponents continue to question the value of mammography. Thus, it is increasingly important that breast imaging care providers understand the nature and results of the randomized controlled trials (RCTs), which have definitively demonstrated that screening mammography in women 40-74 years of age decreases deaths from breast cancer. Cancer localized in the breast is not what causes death; it is breast cancer spread (metastasis) to other organs that causes mortality. The goal of mammographic screening (and other breast cancer screening tests) is to detect breast cancer earlier than it would otherwise manifest clinically, when it is less likely to have spread. Data clearly show that detection of breast cancers at smaller sizes and lower stages is associated with better patient outcomes from lower morbidity and reduced breast cancer deaths. RCTs are the gold standard for proving that early detection with mammography decreases mortality from breast cancer. It is important to understand that the key evidence measure is the breast cancer death rate observed in the experimental group (women invited to have screening mammography) compared to that in the control group (women not invited to have screening mammography). It is not sufficient to use survival time (the time of discovery of the cancer to the date of death) between the groups, as this may reflect “lead-time” bias, in which a cancer is found earlier so survival time appears longer, but the date of death is not altered. -
Evidence Synthesis Number 197 Screening for Hypertension in Adults
Evidence Synthesis Number 197 Screening for Hypertension in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA-290-2015-000017-I-EPC5, Task Order No. 5 Prepared by: Kaiser Permanente Research Affiliates Evidence-based Practice Center Kaiser Permanente Center for Health Research Portland, OR Investigators: Janelle M. Guirguis-Blake, MD Corinne V. Evans, MPP Elizabeth M. Webber, MS Erin L. Coppola, MPH Leslie A. Perdue, MPH Meghan Soulsby Weyrich, MPH AHRQ Publication No. 20-05265-EF-1 June 2020 This report is based on research conducted by the Kaiser Permanente Research Affiliates Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA-290-2015-000017-I-EPC5, Task Order No. 5). The findings and conclusions in this document are those of the authors, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decision makers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients). -
Oklahoma Primary Care Health Care Workforce Gap Analysis
Oklahoma Primary Care Health Care Workforce Gap Analysis DRAFT Prepared by OSU Center for Rural Health OSU Center for Health Sciences Tulsa, Oklahoma June 2015 Table of Contents Table of Figures ..................................................................................................................................................... ii Tables........................................................................................................................................................................ iii Introduction ............................................................................................................................................................ 1 Background & Data Acquisition ...................................................................................................................... 2 Methodology ........................................................................................................................................................... 2 Primary Care Provider Supply ......................................................................................................................... 3 Primary Care Provider Demand ................................................................................................................... 10 Conclusions .......................................................................................................................................................... 12 Limitations ........................................................................................................................................................... -
Primary Care Network Listing | Healthpartners
DHS-6594C-ENG HealthPartners® Minnesota Senior Health Options (MSHO) (HMO SNP) Network April 2018 – September 2018 PRIMARY CARE NETWORK LISTING Minnesota Counties: Anoka, Benton, Carver, Chisago, Dakota, Hennepin, Ramsey, Scott, Sherburne, Stearns, Washington, Wright HealthPartners 8170 33rd Ave S. P.O. Box 1309 Minneapolis, MN 55440-1309 Member Services: 952-967-7029 or 1-888-820-4285 (TTY/TDD 711) Oct. 1 – Feb. 14 8 a.m. to 8 p.m. CT, seven days a week Feb. 15 – Sept. 30 8 a.m. to 8 p.m. CT, Monday – Friday healthpartners.com/msho HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. Enrollment in HealthPartners depends on contract renewal. HealthPartners MSHO Plan 16697_Print April 2018 H2422 108677 DHS Approved 1/25/2018 1-888-820-4285 Attention. If you need free help interpreting this document, call the above number. ያስተውሉ፡ ካለምንም ክፍያ ይህንን ዶኩመንት የሚተረጉምሎ አስተርጓሚ ከፈለጉ ከላይ ወደተጻፈው የስልክ ቁጥር ይደውሉ። مﻻحظة: إذا أردت مساعدة مجانية لترجمة هذه الوثيقة، اتصل على الرقم أعﻻه. သတိ။ ဤစာရြက္စာတမ္းအားအခမဲ့ဘာသာျပန္ေပးျခင္း အကူအညီလုုိအပ္ပါက၊ အထက္ပါဖုုန္းနံပါတ္ကုုိေခၚဆုုိပါ။ kMNt’sMKal’ . ebIG~k¨tUvkarCMnYyk~¬gkarbkE¨bäksarenHeday²tKit«f sUmehATUrs&BÍtamelxxagelI . 請注意,如果您需要免費協助傳譯這份文件,請撥打上面的電話號碼。 Attention. Si vous avez besoin d’une aide gratuite pour interpréter le présent document, veuillez appeler au numéro ci-dessus. Thov ua twb zoo nyeem. Yog hais tias koj xav tau kev pab txhais lus rau tsab ntaub ntawv no pub dawb, ces hu rau tus najnpawb xov tooj saum toj no. -
2020 Complete Guide to Health Benefit Plans
FOR BUSINESSES WITH 1–50 EMPLOYEES 2020 health plan guide 1 Table of contents ABOUT PREMERA ............................ 3 Why businesses choose Premera .................4 WE’RE IN YOUR CORNER ..................... 5 Medical plan support programs ...................5 PROVIDER NETWORKS ....................... 6 Provider network options .........................7 MEDICAL AND DENTAL PLANS ............... 8 Medical plan snapshot ..........................10 Adult vision ....................................12 Medical plans with Family Dental ................13 Adult dental plans ..............................14 Dental plan snapshot ...........................15 Adult Dental Optima™ ...........................16 Adult Dental Optima Voluntary™ .................18 Dental options and requirements ................20 2 We care for our customers The customer is at the center of all we do—that’s why we offer plans that help you keep control of your expenses while giving your employees access to quality and affordable care. 3 Why businesses choose Premera Network strength provides choice and savings • We offer a variety of provider network options so you can choose the level of access that works best for the needs of your employees. Well-rounded benefits package • We make it easy for you to attract and retain the best talent with appealing benefits packages that support the whole health of your employees. • Choose from a range of plans to find the right balance that best fits the needs and budget for both your business and your employees. Tools and programs for employees • Our built-in support programs encourage your employees to engage in their healthcare, leading to healthier, happier employees. • Online tools and apps help your employees find doctors, compare costs of services and medications, access pharmacy information, and review claims. Administrative ease and support • Integrate dental and vision with your medical and pharmacy plans and simplify your work by dealing with only one health plan for all your healthcare administration.